Figures & data
Table 1. The clinical data of liver cancer patient.
Table 2. The clinical data of compensated cirrhosis patients.
Table 3. The clinical data of hepatic hemangioma patients.
Figure 1. Representative western blot of relative protein expression from tissue samples. X: hepatic hemangioma; LC: liver cirrhosis; C: liver cancer; P: pra-carcinoma.
Figure 2. ETAR expression from tissue samples was visualized and localized by confocal microscopy. X: hepatic hemangioma; LC: liver cirrhosis; C: liver cancer; P: para-carcinoma.
Figure 3. ETAR expressions in HSCs. α-SMA was a positive control for HSCs. White arrowheads indicate dual staining and/or close proximity of α-SMA and ETAR expression which could be visualized in merged images. X: hepatic hemangioma; LC: liver cirrhosis; C: liver cancer; P: para-carcinoma.
Figure 4. ETAR expressions in HSECs. CD31 was a positive control for HSECs. White arrowheads indicated dual staining and/or close proximity of α-SMA and ETAR expression which could be visualized in merged images. X: hepatic hemangioma; LC: liver cirrhosis; C: liver cancer; P: para-carcinoma.
Figure 5. ETAR positive cells in liver tissue. X: hepatic hemangioma; LC: liver cirrhosis; C: liver cancer; P: para-carcinoma.
Figure 6. Correlation analysis of ETAR positive cells and clinical indexes. Liver function index included alanine transaminase (ALT), α fetoprotein (AFP), and platelet count (PLT).
Table 4. The analysis of relationship between fluorescent staining results and clinical data.